The Evaluation of a Rapid In Situ HIV Confirmation Test in a Programme with a High Failure Rate of the WHO HIV Two-Test Diagnostic Algorithm by Klarkowski, Derryck B. et al.
The Evaluation of a Rapid In Situ HIV Confirmation Test
in a Programme with a High Failure Rate of the WHO HIV
Two-Test Diagnostic Algorithm
Derryck B. Klarkowski*, Joseph M. Wazome, Kamalini M. Lokuge, Leslie Shanks, Clair F. Mills, Daniel P.
O’Brien
Public Health Department, Me ´decins Sans Frontie `res, Amsterdam, The Netherlands
Abstract
Background: Concerns about false-positiveHIV results led toa reviewof testing proceduresused in a Me ´decinsSansFrontie `res
(MSF) HIV programme in Bukavu, eastern Democratic Republic of Congo. In addition to the WHO HIV rapid diagnostic test
algorithm(RDT)(twopositiveRDTsaloneforHIVdiagnosis)usedinvoluntarycounsellingandtesting(VCT)sitesweevaluatedin
situ a practical field-based confirmation test against western blot WB. In addition, we aimed to determine the false-positive rate
of the WHO two-test algorithm compared with our adapted protocol including confirmation testing, and whether weakly
reactive compared with strongly reactive rapid test results were more likely to be false positives.
Methodology/Principal Findings: 2864 clients presenting to MSF VCT centres in Bukavu during January to May 2006 were
tested using Determine HIV-1/2H and UniGold HIVH rapid tests in parallel by nurse counsellors. Plasma samples on 229
clients confirmed as double RDT positive by laboratory retesting were further tested using both WB and the Orgenics
Immunocomb CombfirmH HIV confirmation test (OIC-HIV). Of these, 24 samples were negative or indeterminate by WB
representing a false-positive rate of the WHO two-test algorithm of 10.5% (95%CI 6.6-15.2). 17 of the 229 samples were
weakly positive on rapid testing and all were negative or indeterminate by WB. The false-positive rate fell to 3.3% (95%CI
1.3–6.7) when only strong-positive rapid test results were considered. Agreement between OIC-HIV and WB was 99.1%
(95%CI 96.9–99.9%) with no false OIC-HIV positives if stringent criteria for positive OIC-HIV diagnoses were used.
Conclusions: The WHO HIV two-test diagnostic algorithm produced an unacceptably high level of false-positive diagnoses in
our setting, especially if results were weakly positive. The most probable causes of the false-positive results were serological
cross-reactivity or non-specific immunereactivity. Our findings show thatthe OIC-HIV confirmationtest is practical and effective
in field contexts. We propose that all double-positive HIV RDT samples should undergo further testing to confirm HIV
seropositivity until the accuracy of the RDT testing algorithm has been established at programme level.
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Introduction
Since 2000, Me ´decins Sans Frontie `res (MSF), in conjunction
with the local Ministry of Health, has run a comprehensive HIV
programme in Bukavu, a city located in the conflict affected
eastern region of the Democratic Republic of Congo (DRC).
Bukavu is home to significant numbers of people displaced by the
conflict that has plagued the region since 1996. In 2004, the HIV
prevalence in Bukavu was estimated to be 3.1%.[1]
Between January 2001 to May 2006, 13,678 clients were tested
for HIV by nurse counsellors using rapid diagnostic tests (RDTs)
performed according to the WHO HIV two-test algorithm
[2].which interprets two positive independent tests as a positive
result. There is no requirement for confirmation testing, which
differs from the standard practice in developed countries, and
there is no differentiation made between strongly and weakly
positive test results. False-positive results with two independent
HIV tests have been reported [3–11], but until recently this
phenomenon was thought to be rare. It has also been assumed that
confirmation testing in resource-limited settings was not feasible.
In late 2004, a group of patients from the MSF/MoH clinics
who had initially tested positive for HIV on the basis of two
positive RDT results were identified as having maintained a high
CD4 count. They were retested with RDTs and shown to be HIV
negative. The results were of great concern since a false-positive
result may have significant adverse outcomes: stigma and
discrimination, abandonment, domestic violence, exposure to
unnecessary and potentially toxic medical treatment, and loss of
confidence in the HIV programme. HIV counselling and testing
practices were reviewed and supervision intensified; however the
false-positive results persisted. The MSF algorithm was changed in
December 2005 to introduce retesting of all VCT positive results
and confirmation testing by Orgenics Immunocomb Combfirm
HIVH (OIC-HIV) and/or western blot (WB). One of the study
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result, some test lines were fainter than others raising the
possibility that these weakly reactive tests may correlate with a
higher risk of false-positive results.
In an observational study, we analysed 5 months9 routine
programmatic data to compare the results obtained using the
WHO 2-test algorithm with our new testing procedures under
programme conditions. Our primary objective was to evaluate the
performance of the OIC-HIV test compared to WB testing as a
practical in situ confirmation test.
Methods
Study population
Testing was performed on consecutive VCT clients, drawn from
both community health education activities and sexually transmitted
infection clinics during January to May 2006. Programme details
and treatment outcomes have been described elsewhere [12].
Testing procedures
Clients were tested using Determine HIV-1/2H and UniGold
HIVH rapid tests in parallel by nurse counsellors. The tests were
performed in the presence of the client using plasma from EDTA
venous blood samples collected and centrifuged immediately
before testing. New gloves were used for each client. The specimen
tube was labelled in front of the client using a unique client
number. Manufacturers’ instructions for test procedures were
followed. Each test was interpreted by the counsellors as a positive
result if both the test and internal control lines were positive. If
both rapid tests were interpreted as positive, the client was
informed that their result was positive but that a confirmation test
would be done and that this might involve referral to an external
laboratory. The individual was offered an immediate appointment
in the HIV clinic, and accompanied to the clinic by the counsellor.
The counsellors further classified the results as strongly positive
if the line had normal colour thickness and intensity or weakly
positive if significantly thinner and weaker than normal positive
results. If at least one of the two positive tests gave a weak result,
the overall result was classified as weak positive.
The client was given a negative result if both tests were negative.
If one test was positive and the other negative, the client was told
the result was indeterminate and needed to be repeated in 6 weeks.
All clients, regardless of the result, received routine counselling on
risk reduction practices.
Training and supervision of the nurse counsellors
Testing was done by the same four counsellors during the study
period. All counsellors had programme experience and received
training from the laboratory supervisor before the study. During
the study period, the counsellors were directly observed perform-
ing the tests on a weekly basis by one of the study authors (JMW).
Daily supervision and psychosocial support was given to
counsellors. Counsellors saw a maximum of eight clients per day
to limit fatigue and ensure quality of testing and counselling.
Quality control of VCT results
All double-positive results, whether weak or strong, were
rechecked in the MSF reference laboratory using the same rapid
test algorithm as that used in the VCT clinics. The laboratory
control was performed unblinded on the same tube of plasma drawn
by the counsellor. The laboratory technician further classified the
results as strong or weak positives using the same criteria as the nurse
counsellors. Samples from clients reported as negative by VCT were
randomly selected for retesting in the laboratory.
Quality control of test kits
All rapid test kits were stored according to manufacturers’
instructions. Quality control was performed using a weak-positive
sample prepared by the MSF reference laboratory on a randomly
selected Determine and Unigold test each week and from every
new box or pack.
Confirmation testing
Plasma samples confirmed as double-positive on RDTs by the
laboratory were tested using OIC-HIV and/or WB (GeneLabs
Diagnostics HIV BLOT 2.2H). OIC-HIV was chosen as it requires
no specialised laboratory equipment and thus can be easily
performed in a peripheral laboratory, takes less than 2 hours, is
easy to interpret, and separately detects p24, p31, gp40, gp120,
and p36 antibodies. In addition, the HIV-OIC test uses
recombinant and peptide antigens as do the RDTs and therefore
can be expected to have similar sensitivity. WB was chosen as it is
the internationally recognised gold standard.
WBs were performed at the National Reference Laboratory,
Kigali, Rwanda. The laboratory was blind to the OIC-HIV results
and the strength of rapid test reactivity. OIC-HIV tests were
performed blind to WB results by the laboratory supervisor in the
MSF referral laboratory.
The WB results were interpreted according to Centers for
Disease Control criteria [13]. The result of the OIC-HIV test was
interpreted according to both the manufacturer’s directions
(interpreting either 2 [gp120 and gp41] HIV envelope (env)
antibodies or gp41 antibody plus 1 core antibody [p24 and/or
p31] as a positive result) and according to a more stringent
criterion requiring a minimum of two env (gp120 and gp41)
antibodies plus one gag (p24) or pol (p31) reaction for a positive
result.
False positive diagnosis
This is defined as a sample that gives a positive test result with
two independent RDT tests, and classified as positive according to
the WHO two-test algorithm, which is not confirmed by WB
testing.
Statistical analysis
Analyses were performed using STATA Version 9 (STATA-
Corp, Texas USA); 95% binomial exact CIs were used.
Ethics review
Informed consent was obtained verbally from all clients before
testing. The study was reviewed and approved by the MSF Ethics
Review Board.
Role of the funding source
There was no specific funding source. The study was funded as
part of routine MSF operations.
Results
Study population
2864 clients received voluntary counselling and testing at the
two test sites during the study period. Approximately 60% of the
clients tested were female. The majority of clients (70%) reported
residence in Bukavu city while the rest came largely from the rural
areas surrounding the city. The most common reasons given for
testing were ‘to know their status’, to confirm results received
elsewhere, or a concern prompted by repeated illness, a sexually
transmitted infection, or a history of sexual violence.
In Situ HIV Confirmation
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Figure 1 shows the flow of test results through the study. During
January–May 2006, there were 365 (12.7%) double-positive
results. Of these, 330 (90.4%) samples were referred to the
laboratory. 35 samples were excluded because the counsellor was
not able to draw a blood sample and therefore tested by finger
prick, or because the sample did not arrive at the laboratory.
Because of field constraints only 229 of the 330 samples were able
to be referred for WB testing, the remainder were tested by OIC-
HIV alone (data not shown). This paper only analyses the samples
tested with both OIC-HIV and the gold standard reference WB
methodology (Figure 1).
The laboratory confirmed all 60 negative VCT rapid test
samples selected for quality control as negative.
Laboratory rapid test, OIC-HIV, and western blot results
Repeat rapid tests were performed on 330 samples. There was
100% agreement between the VCT and laboratory rapid test results
for positive/negative and strong/weak classification. All rapid test
results presented here are laboratory results, not VCT results.
Table 1 shows that for the 229 samples tested by western blot,
205 were positive (203 had $5 HIV-1 bands) and 24 were
negative or indeterminate, which gives an overall false-positive
rate of 10.5% (95%CI 6.6–15.2). Of the 229 samples, 212 (92.6%)
were strong, and 17 (7.4%) were weak, rapid test positives
(Table 1). Seven of the strong positives were negative or
indeterminate by WB, which gives a false-positive rate of 3.3%
(95%CI 1.3–6.7). All 17 of the weak positives were negative or
indeterminate by western blot, which gives a false-positive rate of
100% (95%CI 80.5–100). All 17 weak positives were also negative
or indeterminate by OIC-HIV (Table 1).
Agreement between OIC-HIV and western blot
Table 1 shows minor variations in banding patterns between
OIC-HIV and WB in 19 of the 229 samples. Differences in cross-
reactive patterns can be expected between WB whole viral
antigens and OIC-HIV peptide/recombinant antigens [15]. The
differences do not affect interpretation and are accepted as
agreement.
Using the manufacturer’s directions for interpretation of the
OIC-HIV results, there was agreement between OIC-HIV and
WB in classifying 227 of the 229 samples (99.1% [95%CI 96.9–
99.9%]) as positive or negative/indeterminate (Table 1). For the
two cases of disagreement, OIC-HIV gave a positive result
whereas the WB was indeterminate (single gp41 band). This
represents an over-diagnosis of 0.9%.
Using the more stringent criterion for OIC-HIV positivity,
requiring a minimum of two env and one gag or pol reaction, there
was agreement with the WB classification as positive or negative/
indeterminate in 227 of the 229 samples (99.1% [95%CI 96.9–
99.9%]). The OIC-HIV test gave no false positive results against
WB. For the two cases of disagreement, OIC-HIV gave an
indeterminate result whereas the WB was positive using CDC
criteria [13]. In both cases, only two bands were detected by
western blot.
Discussion
Our findings demonstrate that two positive rapid HIV tests
performed alone gave a 10.5% false positive rate compared to WB
in our program in eastern DRC, and these findings strongly
support the need for confirmation testing of double-positive HIV
RDT test results. False-positive reactions in individual HIV
Figure 1. HIV Testing flowchart.
doi:10.1371/journal.pone.0004351.g001
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9,11,16–19] and ELISA [3–5,8,10,20–23] testing. A common
practice in resource-limited countries, based on the WHO two-test
algorithm [2], is to accept two positive HIV test results as
diagnostic of HIV without performing confirmation testing. This
will give an incorrect diagnosis if a false positive reaction occurs
simultaneously in both tests, and this has been reported for a range
of test brands and in varied locations [3–11]. The finding of a
single gp41 reaction in 50% of our false positive cases is of
particular concern because gp41 is shared by multiple RDT tests
as a target antigen, and can therefore cause double false positive
reactions.
Our study has the limitation that testing was performed under
field conditions where it was not possible to follow up clients with
negative or indeterminate WB results, or further confirm results by
NAAT or p24-antigen testing. Therefore it is possible that some
clients with positive RDT results and negative or indeterminate
WB results may have been in early seroconversion. However a
number of serological findings strongly support cross-reactivity as
the major cause. The finding of a single gp41 band in 12/24 cases
is not consistent with early phase infection and is more consistent
with interference with non-HIV associated anti-gp41 as has been
previously reported [22,24,25]. Further MSF field experience
(data not shown) has demonstrated that Determine can detect
lower levels of HIV antibody than Unigold, and therefore it is
unlikely that the D+
wU+
s and D+
wU+
w results represent early
seroconversion. It has also been reported that only a minority of
indeterminate WB results subsequently seroconvert on follow-up
testing [8,24,26]. None of the false-positive samples were from
late-stage AIDS patients in whom reduced levels of pol and gag
antibodies have been described.
The possibility that the false-positive results were a result of
error in VCT is excluded because the results reported are based on
the results obtained in the laboratory not during VCT. Although
clerical error cannot be excluded it is unlikely given the high
concordance between the results of the OIC-HIV testing
performed in the MSF laboratory, and WB performed in a
blinded manner in the Kigali laboratory. In addition, the false
positives occurred using tests with different batch numbers, hence
it is very unlikely that results were caused by test device error.
17 of the 24 samples that could not be confirmed by WB gave a
weak reaction in one or both RDT tests. This is consistent with
previously reported low specificity for weak reactivity in ELISA
[5,10,20,21] and RDT testing [11,17,19]. Therefore we propose
that programmes that cannot perform confirmatory testing should
repeat weakly reactive test results, and if confirmed interpret such
reactions as an indeterminate rather than positive result, except in
blood donor screening when a weak reaction should be considered
as positive. However, and significantly, an unacceptably high 3.3%
(95%CI: 1.3–6.7%) of double strong RDT positive samples also
could not be confirmed by WB.
For reasons of practicality and cost, WB and molecular biology
(NAAT) confirmation testing is not available in most resource-
limited settings. For this reason we evaluated the OIC-HIV test as
an in situ confirmatory test. This test is simple to use and interpret,
has a relatively low cost compared with WB and NAAT, and
requires no specialized laboratory equipment. Our findings show a
99.1% (95%CI 96.9–99.9%) correlation between OIC-HIV and
Table 1. Analysis of double-positive rapid test results by enzyme immunoassay (OIC-HIV) and western blot (WB) banding pattern
Rapid test results (n=229) OIC-HIV reactions WB banding pattern n
OIC-HIV
result
WB
result
2
Strong rapid test positives;
D+
s U+
s (n=212)
gp120+, gp41+, p24+, p31+ $5 bands including gp120+, gp41+, p24+,p 3 1 + 199 POS POS
gp120+, gp41+, p24+ but p312$ 5 bands including p31+ 1 POS POS
gp120+, gp41+, p31+, p24+ $5 bands but gp1202 3 POS POS
gp41+ p24+ gp41+ p24+ 1 POS
3 POS
gp120+ gp41+ gp120+ p24+ 1 POS
1,3 POS
n confirmed POS by OIC-HIV/WB 205
NEG NEG 1 NEG NEG
NEG p41+ 2 NEG IND
p41+ NEG 1 IND NEG
gp41+ p24+ gp41+ 1 POS
3 IND
gp120+ gp41+ gp41+ 1 POS
3 IND
p24+ p31+ gp41+ 1 IND IND
n IND or NEG by OIC-HIV/WB 7
Weak rapid test positives (n=17)
D+
sU+
w NEG NEG 9 NEG NEG
D+
wU+
s NEG gp41+ 7 NEG IND
D+
wU+
w gp120+ NEG 1 IND NEG
n IND or NEG by OIC-HIV/WB 17
D+
s= Determine HIV-1/2H strong-positive. D+
w= Determine HIV-1/2H weak-positive. U+
s= UniGold HIVH strong-positive. U+
w= UniGold HIVH weak-positive.
POS=positive. NEG= negative. IND= indeterminate.
1The discrepancy between banding patterns in OIC-HIV and WB may have been caused by either laboratory/clerical error, or different patterns of cross-reactivity
between the two tests.
2Using Centers for Disease Control criteria [13].
3Using the manufacturer’s interpretation.
doi:10.1371/journal.pone.0004351.t001
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HIV positives if our proposed criteria were used, although there is
a need for further research to confirm the reliability of this test in
the African context.
However, using the manufacturer’s recommended interpretation
(2 env,o r1env and 1 non-env reaction), the OIC-HIV test gave two
false HIV1-positive results against WB. This may have been caused
bygp41activity;cross-reactinggp41antibodiesinHIV-negativesera
have been reported to cause false gp120 and p24 reactivity [22,25].
Until further data are available, we propose that 2 env and 1 gag or pol
HIV-1 reaction, or 1 env,1gag and 1 pol should be the minimum
requirement for a positive result. This should only delay diagnosis in
a few cases of early seroconversion. In urgent situations, samples
could be further tested by WB, p24 antigen assay, or NAAT
techniques if available. However, the more stringent criterion should
be used with caution in late stage AIDS, where p24 and p31
antibodies decline [27], or for screening blood donors. While there
was close correlation between the reaction patterns of WB and OIC-
HIV for the positive samples, there was considerable variability in
the negative and indeterminate samples. We suggest the discordance
was due to different reactivities of recombinant, peptide, and native
viral antigens to cross-reacting antibodies [15,28].
Our study design did not allow an analysis of factors causing
cross reactivity, although several possibilities exist. Firstly, there is
a high degree of HLA polymorphism among Africans [29], and
because HLA class II antigens directly modulate the immune
response [30], our population might have a heightened immune
response to a commonly occurring infectious agent resulting in
atypical frequency of cross-reactivity.
A further possibility is that non-specific polyclonal B-lympho-
cyte antibodies formed in any early immune response may
interfere with HIV serological testing [15,23,31]. Such activity
may be heightened in resource-limited settings by general immune
activation due to multiple concomitant infections [32–34]. Gasaira
et al [23] report that HIV false-positives were significantly more
common in young children. The authors speculated that younger
children have a less developed immune system against malaria and
are therefore more likely to exhibit non-specific B-lymphocyte
stimulation producing antibodies that cross-react with HIV
antigens. Most of the WBs on false positive sera in their study
showed gp41 and p51 reactivity. While most of our clients were
adults, the study region has a recent history of population
movement, and displaced persons are likely to have lower
immunity to local diseases and be more likely to exhibit broad
immune responses. Non-specific polyclonal antibody interference
is consistent with our observed high frequency of weak positives
and their low specificity. If such interference was a contributory
factor to the false-positive rate, this would have implications for the
testing of children, refugees, and internally displaced populations.
Our findings have important implications for scale-up of
treatment in areas of low HIV prevalence. The PPV of the
WHO two-test algorithm [2] is based on the assumption that each
test performs independently. We found the PPV of the screening
algorithm to be 89.6% at a prevalence of 11.4%; at an HIV
prevalence of 5% and 2%, if the sensitivity and specificity of the
tests is unchanged, the rapid-test-only protocol will give a PPV of
77.8% and 57.6% respectively. While it is impossible to determine
the generalisability of our population, these results are concerning.
We therefore propose that all double-positive HIV rapid test
samples should undergo further testing to confirm HIV seropos-
itivity until the accuracy of the testing algorithm has been
established at the individual programme level. We have found this
to be feasible in our settings using OIC-HIV. While rapid tests are
an essential tool in efforts to make life-saving treatment available
to those infected with HIV in resource-limited settings, the
accuracy of rapid test algorithms, the low PPV of weakly reacting
rapid tests, and alternatives to WB for confirmatory testing merit
investigation.
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